Source disclosure: February 10, 2026
KOBAYASHI PHARMACEUTICAL CO.,LTD. [4967.T]
TOKYO, Feb 10 (Pulse News Wire) – Kobayashi Pharmaceutical CO.,LTD. (4967.T) reported progress on its prevention measures related to the red yeast rice incident since August 5, 2025.
The company has implemented various initiatives aimed at enhancing product quality and safety awareness among employees and improving internal control systems. Key actions include comprehensive employee training programs, regular communication from top management, and increased dialogue opportunities between executives and staff involved in maintaining product quality. Additionally, the firm established specialized departments focused on regulatory compliance and enhanced external audits by third-party organizations.
In further efforts to strengthen corporate governance, Kobayashi plans to transition to a system with an audit committee by March 2026, contingent upon shareholder approval. The company also revised its human resources evaluation system to prioritize contributions to quality and safety, ensuring a more robust organizational culture aligned withintegrity principles. Moreover, Kobayashi is streamlining its portfolio by reducing non-core SKUs, aiming to eliminate approximately 1,000 SKUs within two years.
This realignment allows for greater focus on essential products and services, reinforcing the company's commitment to quality and safety.
AI-translated content. 🟢 Confidence: High See terms • Original filing